Sanofi, intent on slimming down, mulls $200M-plus sale of anti-inflammation meds: report

Sanofi is in the middle of an ambitious reorganization, spearheaded by CEO Paul Hudson, to slash expenses and pivot toward blockbuster Dupixent. Now, the company is reportedly mulling an asset sale that could net a few hundred million and streamline operations further.

The French drugmaker is shopping a clutch of older anti-inflammatory medicines in a deal that could fetch as much as $234 million, Bloomberg reported.